Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients

Background: Atopic dermatitis (AD) is an inflammatory skin disease characterized by a wide phenotypic variety with a very complex pathophysiological mechanism that has led to the identification of new therapeutic targets, such as janus kinasis (JAK) inhibitors. Objectives: To evaluate the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Radi, Giulia, Simonetti, Oriana, Rizzetto, Giulio, Diotallevi, Federico, Molinelli, Elisa, Offidani, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623121/
https://www.ncbi.nlm.nih.gov/pubmed/34828623
http://dx.doi.org/10.3390/healthcare9111575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623121/
https://www.ncbi.nlm.nih.gov/pubmed/34828623
http://dx.doi.org/10.3390/healthcare9111575

Ejemplares similares